E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
MYELODYSPLASTIC SYNDROMES |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Blood and lymphatic diseases [C15] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | HLT |
E.1.2 | Classification code | 10028536 |
E.1.2 | Term | Myelodysplastic syndromes |
E.1.2 | System Organ Class | 100000004851 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
1.Phase I:
To determine the maximal tolerated dose (MTD) and dose limiting toxicities (DLTs) of increasing doses of IV Acadesine administered on D1, D3, D5, D8, D10 and D12 of a 28 to 56 day-course (cycle length based on the toxicities recovery).
2.Phase II:
To confirm safety and hematological toxicity in 18 additional patients
|
|
E.2.2 | Secondary objectives of the trial |
1.Phase I:
To determine response rates, as defined by the 2006 modified IWG criteria,
•To evaluate response duration, time to IPSS progression, and loss of RBC transfusion independence in these patients.
•To evaluate hospitalization duration, rates of rehospitalization for non-hematological toxicities, severe bleeding or febrile neutropenia.
2.Phase II:
To determine:
•response rate as defined by the 2006 modified IWG criteria
•toxicity profile and safety
•response duration
•rate of progression to AML
•overall survival |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Patients must meet all of the following criteria to participate in the study:
1.Myelodysplastic syndrome including the following categories of the WHO classification: refractory anemia with excess blasts (RAEB), non-proliferative chronic myelomonocytic leukemia (CMML) (leukocytes < 13 G/L but > 10% marrow blasts), AML with 20-30% marrow blasts (RAEB-T according to the FAB classification)
2.Prior treatment with azacitidine or Decitabine for at least 6 courses without response (CR, PR, marrow CR or stable disease with HI according to IWG 2006 criteria) or relapsing after a response
3.IPSS score >1 (IPSS: Int-2 or High);
4.Age ≥ 18 years;
5.Normal liver function, defined by total bilirubin and transaminases less than 1.5 time the upper limit of normal;
6.Normal renal function, defined by creatinine less than 1.5 time the upper limit of normal, creatinine clearance ≥ 50 mL/min.
7.Patient ineligible for allogeneic hematopoietic stem cell transplantation;
8.Written informed consent;
9.Patient must understand and voluntarily sign consent form;
10.Patient must be able to adhere to the visit schedule as outlined in the study and follow protocol requirements;
11.ECOG performance status between 0-2 at the time of screening;
12.Women of childbearing potential must: Agree to use effective contraception without interruption throughout the study and for a further 1 month after the end of treatment;
13.Men must: Agree to not conceive during the treatment and to use effective contraception during the treatment period (including periods of dose reduction or temporary suspension) and for a further 1 month after the end of treatment if their partner is of childbearing potential.
|
|
E.4 | Principal exclusion criteria |
1.Severe infection or any other uncontrolled severe condition
2.Significant cardiac disease - NYHA Class III or IV or having suffered a myocardial infarction in the last 6 months
3.Less than 30 days since prior treatment with growth factors (EPO, G-CSF)
4.Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea. The patient must have recovered from all acute toxicities from any previous therapy.
5.Active cancer, or cancer during the year prior to trial entry other than basal cell carcinoma or carcinoma in situ of the cervix or breast;
6.Patient already enrolled in another therapeutic trial of an investigational drug;
7.HIV infection or active hepatitis B or C;
8.Women who are or could become pregnant or who are currently breastfeeding;
9.Any medical or psychiatric contraindication that would prevent the patient from understanding and signing the informed consent form;
10.Patient eligible for allotransplantation.
11.Known allergy to acadesine or any of its excipients
12.No affiliation to an insurance system
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Phase I:
Safety of Acadesine. It will be analyzed after 1 cycle, and the decision to continue to the dose level above and to enroll 3 additional patients will be taken after assessment of the first patients enrolled by an independent data safety monitoring committee (DSMC), in association with the investigators.
Phase II:
Number of complete Remission (CR), Partial Remission (PR), Marrow CR and stable disease with Hematological Improvement (HI) according to IWG 2006 criteria (see appendix 6).
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Phase I: Toxicity, evaluated using NCI-CTCAE V4.0 criteria.
Phase II: response, according to IWG 2006 criteria. |
|
E.5.2 | Secondary end point(s) |
•Total percentage of response, including all patients achieving CR, PR, marrow CR or stable disease with hematologic improvement, evaluated according to IWG 2006 criteria (after 2, 4 and 6 treatment cycles).
•Duration of response, measured from the date an objective response was achieved to the date of relapse or progression or the date of last contact if no event occurred.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
to determine:
- the duration of the response
- overall survival
- the safety profile
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
Testing three levels of dose of Acadesine |
|
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 9 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |